Tumori intestino

Tumori dell'intestino

Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract

Br J Cancer.1993 Jun;67(6):1404-7.
Lissoni P, Barni S,Tancini G, Ardizzoia A, Rovelli F, Cazzaniga M, Brivio F, Piperno A, Aldeghi R, Fossati D, et al.
The immunotherapy with low-dose IL-2 plus MLT (50mg/day orally) is a new well tolerated and effective therapy of advanced tumours of digestive tract.
Interleukin 2 (IL-2) plus MLT.

A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma

Br J Cancer. 1994 Jan;69(1):196-9.
Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, Brivio F, Tisi E, Rovelli F, Rescaldani R, et al.
The concomitant administration of MLT (40 mg day orally) may increase the efficacy of low-dose IL-2 subcutaneous therapy.Tumour objective regression rate was 11/41 vs 1/39, P < 0.001.
Interleukin 2 (IL-2) plus MLT.

Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo

Neuro Endocrinol Lett. 2002 Apr;23 Suppl 1:50-4.
Winczyk K, Pawlikowski M, Lawnicka H, Kunert-Radek J, Spadoni G, Tarzia G, Karasek M.
Oncostatic effect of MLT depends on acting via both MT(2) and RZR/ROR nuclear receptors.
Nuclear orphan receptors ( RZR/ROR).

Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer

Tumour Biol. 2002 Sep-Oct;23(5):298-302.
Winczyk K, Pawlikowski M, Guerrero JM, Karasek M.
CGP 55644 (antagonist of the nuclear RZR/ROR alpha receptor) given together MLT blocked its pro-apoptotic effect, MLT strongly lowered the P/A ratio (proliferation/apoptosis).
Oncostatic action.

Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorour

Anticancer Res. 2003 Mar-Apr;23(2C):1951-4.
Cerea G, Vaghi M, Ardizzoia A, Villa S,Bucovec R,Mengo S, Gardani G, Tancini G, Lissoni P.
Concomitant administration of MLT (orally at 20 mg/day) and irinotecan (CPT-11) in patients with metastatic colorectal cancer: partial response (PR) was in 5 out of 14, stable disease (SD) in 7 out of 14, disease-control achieved in patients was 12 out of 14, p < 0.05.
Antioxidant and immuno-modulating effects.

Circadian fluctuations of melatonin, tumor necrosis factor-alpha and its soluble receptors in the circulation of patients with advanced gastrointestinal cancer

J Exp Clin Cancer Res. 2003 Jun;22(2):171-8.
Muc-Wierzgon M, Nowakowska-Zajdel E, Zubelewicz B, Wierzgon J, Kokot T, Klakla K, Szkilnik R, Wiczkowski A.
May suggest the presence of self-regulation mecha-nisms between the neuroendocrine system and the cytokine network in advanced cancer patients.
Tumor necrosis factor alpha (TNFalpha).

Luzindole but not 4-phenyl-2- propionamidotetralin (4P-PDOT) diminishes the inhibitory effect of melatonin on murine Colon 38 cancer growth in vitro

Neuro Endocrinol Lett. 2009;30(5):657-62.
Winczyk K, Fuss-Chmielewska J, Lawnicka H, Pawlikowski M, Karasek M.
Melatonin at (10-7, 10-9 M) significantly decreased the viability of Colon 38 cancer cells.
Oncostatic action of MLT

The melatonin action on stromal stem cells within peri-cryptal area in colon cancer model under constant light

Biochem Biophys Res Commun. 2011 Feb 25;405(4):593-8.
Kannen V, Marini T, Zanette DL, Frajacomo FT, Silva GE, Silva WA Jr, Garcia SB.
MLT showed a great potential to control the preneo-plastic patterns induced by constant light (LL).
MLT-supplementation (10mg/kg/day).


Abbonamento a RSS - Tumori intestino